Compare BBGI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBGI | CALC |
|---|---|---|
| Founded | 1961 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.7M |
| IPO Year | 1999 | 2020 |
| Metric | BBGI | CALC |
|---|---|---|
| Price | $22.89 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 26.5K | ★ 1.0M |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.77 | 0.30 |
| Revenue | ★ $232,179,463.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.56 | ★ $2.31 |
| Revenue Growth | ★ 69.89 | N/A |
| 52 Week Low | $3.14 | $0.46 |
| 52 Week High | $29.30 | $7.20 |
| Indicator | BBGI | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 42.02 |
| Support Level | $3.72 | $0.52 |
| Resistance Level | $25.26 | $0.76 |
| Average True Range (ATR) | 2.02 | 0.12 |
| MACD | -0.59 | -0.03 |
| Stochastic Oscillator | 15.05 | 11.16 |
Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.